<DOC>
	<DOCNO>NCT01024829</DOCNO>
	<brief_summary>Increasing ( `` boost '' ) radiation dose patient non-small cell lung carcinoma individual maximal dose safely give . The question patient receive boost whole tumor part tumor . Therefore patient randomize one two treatment option . All patient receive 24 radiation . Dose increasement enable call integrated boost . Furthermore : - PET image hypoxia use [ 18F ] HX4 , single injection PET CT scan two four hour post injection .</brief_summary>
	<brief_title>Dose Escalation Boosting Radiation Dose Within Primary Tumor Using FDG-PET-CT Scan Stage IB , II III NSCLC</brief_title>
	<detailed_description>A randomized phase II study conduct patient inoperable stage IB , II III non-small cell lung cancer ( NSCLC ) . The patient randomize receive standard 66 Gy give 24 fraction 2.75 Gy integrate boost primary tumor whole ( Arm A ) integrate boost 50 % SUVmax area primary tumor ( pre-treatment FDG-PET scan ) ( Arm B ) . Both treatment arm may combine chemotherapy ( concurrent sequential ) . Patients fulfil eligibility criterion register study , initial radiotherapy treatment planning perform . When integrated boost primary tumor whole 72 Gy possible dose constraint , patient receive 66 Gy low accord normal tissue tolerance ( see ) . They randomize , follow trial . As , clear proportion patient receive integrate boost outcome dose-escalation possible . Stage IB-II patient receive radiotherapy alone , stage III patient combine chemotherapy radiation . The patient may receive induction chemotherapy two cycle registration trial . The statistical calculation perform deal patient heterogeneity . The primary objective study determine local progression-free survival ( LPFS ) 1 year . Secondary objective - Toxicity function radiotherapy dose volume tissue irradiate . - Overall survival . - Quality life Furthermore : - PET image hypoxia use [ 18F ] HX4 , single injection PET CT scan two four hour post injection . - Dynamic Contrast-Enhanced CT imaging</detailed_description>
	<criteria>1 . Patients &gt; 18 year subtype pathologically proven ( biopsy cytology ) , nonsmall cell lung cancer . The diagnosis may establish biopsy cytology obtain primary tumor and/ metastatic lymph node . 2 . Minimal diameter primary tumor 4 cm , allow boost subvolumes . 3 . UICC TNM Stage T24 , N03 , M0 disease ( TNM definition see appendix 2 ) . 4 . Only stage IBII patient nog candidate surgery study candidate . 5 . Measurable disease registration . 6 . ECOGperformance status ≤ 2 ( see appendix 6 ) 7 . Lung function : FEV1 DLCO least 40 % ageadjusted normal value 8 . Willing able give write informed consent . 9 . Patients locoregional recurrent lung tumor follow surgery second primary cancer ( least 3 year treatment ) eligible , unless pneumonectomy perform . 10 . SUVmax pretreatment FDGPET scan ≥ 5 primary tumor . 11 . Adequate organ function , include follow : Adequate bone marrow reserve : absolute neutrophil ( segmented band ) count ( ANC ) ≥ 1.5 x 109/L , platelet ≥ 100 x 109/L , hemoglobin ≥ 9 g/dL . Hepatic : bilirubin ≤ 1.5 time upper limit normal ( x ULN ) ; alkaline phosphatase ( AP ) , aspartate aminotransferase ( ASAT ) , alanine aminotransferase ( ALAT ) ≤ 3.0 x ULN ( AP , AST , ALT ≤ 5 x ULN acceptable liver tumor involvement ) . Renal : calculated creatinine clearance ( CrCl ) ≥ 45 ml/min base original weight base Cockcroft Gault formula 12 . For woman : Must surgically sterile , postmenopausal , compliant highly reliable contraceptive method ( failure rate &lt; 1 % ) 6 month treatment period ; must negative serum urine pregnancy test within 7 day study enrollment must breastfeed . 13 . For men : Must chemotherapy take adequate contraceptive measure . 1 . Prior radiotherapy thorax . 2 . Clinical superior vena cava syndrome , malignant pleural effusion malignant pericardial effusion . 3 . T4 , specify : Tumor growth large blood vessel spiral CT scan encasement &gt; 50 % 4. multiple nodule ipsilateral lobe ( ) . 5 . Postobstructive atelectasis infiltration distinguish tumor CTPET scan . 6 . Patients diagnosis cancer within last 3years ( except situ carcinoma 's / nonmelanoma skin cancer ) . 7 . Pregnant woman , lactate woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Non small cell lung cancer</keyword>
	<keyword>Inoperable</keyword>
	<keyword>HX4</keyword>
</DOC>